{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":2,"sponsored":0,"items":[{"id":"n_zkid52l47kayvendgpja","seq":422123,"kind":"official","title":"8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)","url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526403424/0001193125-26-403424-index.htm","summary":"Filed: 2026-09-28 AccNo: 0001193125-26-403424 Size: 150 KB Item 8.01: Other Events","published":"2026-09-28T12:05:05Z","seen":"2026-09-28T12:20:49Z","lang":"en","country":"US","source":{"id":"sec-edgar","name":"SEC EDGAR (current filings","domain":"sec.gov","outlet":{"wikidata":"Q953944","name":"United States Securities and Exchange Commission","type":"government","country":"US","designations":["financial regulatory agency","independent agency of the united states government","regulatory agency"]}},"via":"sec-edgar","topics":["form type"],"entities":[{"id":"Q124433826","name":"4D Molecular Therapeutics, Inc.","type":"org"}],"story":"st_oud32giy6r2doesz5rsa","category":"economy-business","category_p":0.31,"category2":"health","sentiment":"neutral","tone":-0.05,"political":0.03},{"id":"n_xc6kuintt6rj4xo6t3vq","seq":419254,"kind":"press_release","title":"4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME","url":"https://www.globenewswire.com/news-release/2026/09/28/3369825/0/en/4dmt-advances-4d-150-into-phase-3-for-second-large-market-retina-indication-with-initiation-of-4sight-in-dme.html","summary":"EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic…","published":"2026-09-28T12:00:00Z","seen":"2026-09-28T12:07:22Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:fdmt","us35104e1001"],"entities":[{"id":"Q124433826","name":"4D Molecular Therapeutics, Inc.","type":"org"}],"mentions":2,"story":"st_xc6kuintt6rj4xo6t3vq","category":"science-technology","category_p":0.62,"category2":"economy-business","sentiment":"neutral","tone":0.39,"political":0.04}]}